Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591081 | 0.87 | ATAD2 (0.36) | ATAD2PDK2PDK4L3MBTL1PGR | |
| SCHEMBL3585335 | 0.80 | NR1H2 (0.40) | ATAD2PDK2PDK4L3MBTL1 | |
| SCHEMBL13382907 | 0.78 | HTR6 (0.37) | ATAD2PDK2PDK4L3MBTL1 | |
| SCHEMBL3594073 | 0.72 | MGAT2 (0.37) | PDK2PDK4PGR | |
| SCHEMBL3596379 | 0.72 | MGAT2 (0.37) | PDK2PDK4PGR | |
| SCHEMBL3600184 | 0.70 | MEN1 (0.44) | PGR | |
| SCHEMBL3591085 | 0.70 | NR1H2 (0.37) | ATAD2PDK2PDK4L3MBTL1PGR | |
| SCHEMBL3599451 | 0.67 | PDK2 (0.44) | ATAD2PDK2PDK4L3MBTL1PGR | |
| SCHEMBL3606355 | 0.67 | PDK2 (0.36) | PDK2PDK4L3MBTL1 | |
| SCHEMBL3593368 | 0.64 | PDK2 (0.34) | ATAD2PDK2PDK4PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | ATAD2 1819/4885PDK2 3637/4885PDK4 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.